



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

Clatterbridge Road  
Bebington  
Wirral  
CH63 4JY

Tel: 0151 556 5000  
Web: [www.clatterbridgecc.nhs.uk](http://www.clatterbridgecc.nhs.uk)

Date: 1 June 2018

**Re: Freedom of Information Request**  
**Ref: 96-2018**

Thank you for your email dated 9th May 2018 requesting information with regards to treatment.

**Please see Appendix 1 for the information requested.**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**

## Appendix 1

### Metastatic Squamous Cell Non-small cell lung cancer (NSCLC): In the past 3 months, how many patients were treated with:

<b>Atezolizumab (Tecentriq)</b>	<b>0</b>										
<b>Pembrolizumab (Keytruda)</b>	<b>21</b>										
<b>Nivolumab (Opdivo)</b>	<b>6</b>										
<b>Other active systemic anti-cancer therapy</b>	<b>27</b> <table border="0" style="width: 100%;"> <tr> <td>Carboplatin + Gemcitabine</td> <td style="text-align: right;">16</td> </tr> <tr> <td>Carboplatin + Vinorelbine</td> <td style="text-align: right;">6</td> </tr> <tr> <td>Cisplatin + Gemcitabine</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Crizotinib</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Docetaxel</td> <td style="text-align: right;">3</td> </tr> </table>	Carboplatin + Gemcitabine	16	Carboplatin + Vinorelbine	6	Cisplatin + Gemcitabine	1	Crizotinib	1	Docetaxel	3
Carboplatin + Gemcitabine	16										
Carboplatin + Vinorelbine	6										
Cisplatin + Gemcitabine	1										
Crizotinib	1										
Docetaxel	3										
<b>Palliative care only</b>	<b>Not applicable as the Trust does not provide “Palliative Care Only”, in these instances patients would be referred to their local palliative care services</b>										

### Metastatic Non Squamous Cell Non-small cell lung cancer (NSCLC): In the past 3 months, how many patients were treated with:

<b>Atezolizumab (Tecentriq)</b>	<b>0</b>																																								
<b>Pembrolizumab (Keytruda)</b>	<b>62</b>																																								
<b>Nivolumab (Opdivo)</b>	<b>1 (Checkmate 817 Trial)</b>																																								
<b>Other active systemic anti-cancer therapy</b>	<b>170</b> <table border="0" style="width: 100%;"> <tr> <td>[TRIAL] ABOUND2L+-ABRAXANE</td> <td style="text-align: right;">1</td> </tr> <tr> <td>[TRIAL] ATLANTIS(B)-CAV</td> <td style="text-align: right;">1</td> </tr> <tr> <td>[TRIAL] ATLANTIS-DOX LURBIN'TEDIN</td> <td style="text-align: right;">1</td> </tr> <tr> <td>[TRIAL] CHECKMATE817-NIVOL IPILIM</td> <td style="text-align: right;">2</td> </tr> <tr> <td>[TRIAL] FOOD EFFECT-CERITINIB</td> <td style="text-align: right;">2</td> </tr> <tr> <td>[TRIAL] MO29872 PS2-ATEZOLIZUMAB</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Afatinib</td> <td style="text-align: right;">21</td> </tr> <tr> <td>Carboplatin + Etoposide</td> <td style="text-align: right;">33</td> </tr> <tr> <td>Carboplatin + Gemcitabine</td> <td style="text-align: right;">9</td> </tr> <tr> <td>Carboplatin + Pemetrexed</td> <td style="text-align: right;">5</td> </tr> <tr> <td>Carboplatin + Vinorelbine</td> <td style="text-align: right;">23</td> </tr> <tr> <td>Carboplatin AUC 2 - 5</td> <td style="text-align: right;">3</td> </tr> <tr> <td>CAV - Cyclophosphamide + Doxorubicin + Vincristine</td> <td style="text-align: right;">2</td> </tr> <tr> <td>Ceritinib</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Cisplatin + Etoposide</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Cisplatin + Pemetrexed</td> <td style="text-align: right;">9</td> </tr> <tr> <td>Cisplatin + Vinorelbine</td> <td style="text-align: right;">1</td> </tr> <tr> <td>Crizotinib</td> <td style="text-align: right;">4</td> </tr> <tr> <td>Docetaxel</td> <td style="text-align: right;">3</td> </tr> <tr> <td>Docetaxel + Nintedanib</td> <td style="text-align: right;">3</td> </tr> </table>	[TRIAL] ABOUND2L+-ABRAXANE	1	[TRIAL] ATLANTIS(B)-CAV	1	[TRIAL] ATLANTIS-DOX LURBIN'TEDIN	1	[TRIAL] CHECKMATE817-NIVOL IPILIM	2	[TRIAL] FOOD EFFECT-CERITINIB	2	[TRIAL] MO29872 PS2-ATEZOLIZUMAB	1	Afatinib	21	Carboplatin + Etoposide	33	Carboplatin + Gemcitabine	9	Carboplatin + Pemetrexed	5	Carboplatin + Vinorelbine	23	Carboplatin AUC 2 - 5	3	CAV - Cyclophosphamide + Doxorubicin + Vincristine	2	Ceritinib	1	Cisplatin + Etoposide	1	Cisplatin + Pemetrexed	9	Cisplatin + Vinorelbine	1	Crizotinib	4	Docetaxel	3	Docetaxel + Nintedanib	3
[TRIAL] ABOUND2L+-ABRAXANE	1																																								
[TRIAL] ATLANTIS(B)-CAV	1																																								
[TRIAL] ATLANTIS-DOX LURBIN'TEDIN	1																																								
[TRIAL] CHECKMATE817-NIVOL IPILIM	2																																								
[TRIAL] FOOD EFFECT-CERITINIB	2																																								
[TRIAL] MO29872 PS2-ATEZOLIZUMAB	1																																								
Afatinib	21																																								
Carboplatin + Etoposide	33																																								
Carboplatin + Gemcitabine	9																																								
Carboplatin + Pemetrexed	5																																								
Carboplatin + Vinorelbine	23																																								
Carboplatin AUC 2 - 5	3																																								
CAV - Cyclophosphamide + Doxorubicin + Vincristine	2																																								
Ceritinib	1																																								
Cisplatin + Etoposide	1																																								
Cisplatin + Pemetrexed	9																																								
Cisplatin + Vinorelbine	1																																								
Crizotinib	4																																								
Docetaxel	3																																								
Docetaxel + Nintedanib	3																																								

	Erlotinib Gefitinib Lorlatinib Nintedanib Octreotide Osimertinib Pemetrexed Topotecan	4 11 1 3 3 5 14 3
<b>Palliative care only</b>	<b>Not applicable as the Trust does not provide “Palliative Care Only”, in these instances patients would be referred to their local palliative care services</b>	

**Adjuvant Melanoma:**

**In the past three months:**

**How many patients were seen who had stage III resectable melanoma?**

**The Trust is unable to answer as the trust does not provide surgery.**

**Of all stage III patients seen, how many received a complete resection?**

**The Trust is unable to answer as the trust does not provide surgery.**

**Of all stage III patients seen, how many were stage III a?**

**The Trust is unable to answer as the trust does not provide surgery.**